Oxaliplatin induces a delayed immune-mediated hemolytic anemia: A case report and review of the literature

Clinical Colorectal Cancer

Volumn 5, Issue 4, 2005, Pages 283-286

  Noronha, Vanita ^a   Burtness, Barbara ^b   Murren, John ^c   Duffy, Thomas P ^c  

^a PC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Disease free survival; FOLFOX regimens; Monoclonal antibodies

Indexed keywords

BEVACIZUMAB; CALCIUM; COMPLEMENT COMPONENT C3D; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IMMUNOGLOBULIN G; MAGNESIUM; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; WARFARIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD SMEAR; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; COOMBS TEST; DRUG TOLERANCE; FEMALE; HEMATOCRIT; HEMICOLECTOMY; HUMAN; ILEOCECAL VALVE; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LEUKOCYTE COUNT; NEUTROPENIA; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOPLASTIN TIME; TREATMENT OUTCOME; URINALYSIS; CASE REPORT; CECUM TUMOR; CHEMICALLY INDUCED DISORDER; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; HEMOLYTIC ANEMIA; ILEUM TUMOR; INTESTINE TUMOR; MIDDLE AGED; REVIEW;

ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CECAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; FLUOROURACIL; HUMANS; HYPERSENSITIVITY, DELAYED; ILEAL NEOPLASMS; INTESTINAL NEOPLASMS; LEUCOVORIN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 33644833923     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.041     Document Type: Article

References (22)

1. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92:1976-1983.
2. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.
3. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11:690-696.
4. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 2004; 95:165-172.
5. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or Cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20:2031-2037.
6. Zelek L, Cottu P, Tubiana-Hulin M, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20:2551-2558.
7. Degardin M, Cappelaere P, Krakowski I, et al. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1996;32:278-279.
8. Chau I, Webb A, Cunningham D, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115:786-792.
9. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
10. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
11. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
12. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29:11-20.
13. Taleghani BM, Fontana S, Meyer O, et al. Oxaliplatin-induced immune pancytopenia. Transfusion 2005; 45:704-708.
14. Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67:179-182.
15. Hofheinz RD, Nguyen XD, Buchheidt D, et al. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol 2004; 53:276-277.
16. Earle CC, Chen WY, Ryan DP, et al. Oxaliplatin-induced Evan's syndrome. Br J Cancer 2001; 84:441.
17. Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000; 11:497.
18. Desrame J, Broustet H, Darodes de Tailly P, et al. Oxaliplatin-induced haemolytic anaemia. Lancet 1999; 354:1179-1180.
19. Sorbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001; 40:882-883.
20. Chen VM, Thrift KM, Morel-Kopp MC, et al. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion 2004; 44:838-843.
21. Getaz EP, Beckley S, Fitzpatrick J, et al. Cisplatin-induced hemolysis. N Engl J Med 1980; 302:334-335.
22. Maloisel F, Kurtz JE, Andres E, et al. Platin salts-induced hemolytic anemia: Cisplatin- and the first case of carboplatin-induced hemolysis. Anticancer Drugs 1995; 6;324-326.